NFG
BCRX icon

Next Financial Group’s BioCryst Pharmaceuticals BCRX Stock Holding History

Next Financial Group’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-100
Closed -$1K – 2623
2021
Q1 		$1K Buy
+100
New +$1.03K ﹤0.01% 2377
2015
Q4 		– Sell
-200
Closed -$2K – 1776
2015
Q3 		$2K Buy
+200
New +$2.67K ﹤0.01% 1599

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Next Financial Group's BCRX Position: Q2 2021 in Review

Next Financial Group sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2021, closing a stake of 100 shares — an estimated $1K sold.

Next Financial Group first reported a position in BCRX in Q3 2015 and held it in 2 quarters. The position peaked at $2K in Q3 2015. 195 funds tracked by Wall St. Rank hold BCRX as of Q2 2021.

  • Next Financial Group reported no remaining BioCryst Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Next Financial Group sold 100 BioCryst Pharmaceuticals shares in Q2 2021, an estimated $1K.
  • Next Financial Group first reported a position in BioCryst Pharmaceuticals in Q3 2015 and held it in 2 quarters.
  • Next Financial Group's BioCryst Pharmaceuticals position peaked at $2K in Q3 2015.
  • 195 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2021.

Based on Next Financial Group's 13F filing for Q2 2021, filed 13 Jul 2021.